Unknown

Dataset Information

0

Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.


ABSTRACT: Malaria deaths have been decreasing over the last 10-15 years, with global mortality rates having fallen by 47% since 2000. While the World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) to combat malaria, the emergence of artemisinin resistant strains underscores the need to develop new antimalarial drugs. Recent in vivo efficacy improvements of the historical antimalarial ICI 56,780 have been reported, however, with the poor solubility and rapid development of resistance, this compound requires further optimization. A series of piperazine-containing 4(1H)-quinolones with greatly enhanced solubility were developed utilizing structure-activity relationship (SAR) and structure-property relationship (SPR) studies. Furthermore, promising compounds were chosen for an in vivo scouting assay to narrow selection for testing in an in vivo Thompson test. Finally, two piperazine-containing 4(1H)-quinolones were curative in the conventional Thompson test and also displayed in vivo activity against the liver stages of the parasite.

SUBMITTER: Neelarapu R 

PROVIDER: S-EPMC6610884 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.

Neelarapu Raghupathi R   Maignan Jordany R JR   Lichorowic Cynthia L CL   Monastyrskyi Andrii A   Mutka Tina S TS   LaCrue Alexis N AN   Blake Lynn D LD   Casandra Debora D   Mashkouri Sherwin S   Burrows Jeremy N JN   Willis Paul A PA   Kyle Dennis E DE   Manetsch Roman R  

Journal of medicinal chemistry 20180209 4


Malaria deaths have been decreasing over the last 10-15 years, with global mortality rates having fallen by 47% since 2000. While the World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) to combat malaria, the emergence of artemisinin resistant strains underscores the need to develop new antimalarial drugs. Recent in vivo efficacy improvements of the historical antimalarial ICI 56,780 have been reported, however, with the poor solubility and rapid  ...[more]

Similar Datasets

| S-EPMC3349818 | biostudies-literature
| S-EPMC9247345 | biostudies-literature
| S-EPMC4234439 | biostudies-literature
| S-EPMC9233739 | biostudies-literature
| S-EPMC2850272 | biostudies-literature
| S-EPMC3873811 | biostudies-literature
| S-EPMC6047022 | biostudies-literature
| S-EPMC10012268 | biostudies-literature
| S-EPMC8521607 | biostudies-literature
| S-EPMC3369735 | biostudies-literature